Investigational drug study for advanced liver cancer
In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.
Catherine Frenette, MD
This study will evaluate the safety and effectiveness of an investigational immunotherapy drug called atezolizumab, in combination with a chemotherapy drug called cabozantinib, for treating patients with advanced liver cancer using. All treatments and physician visits will take place at Scripps Clinic Torrey Pines.
Be 18 years of age or older
Have been diagnosed with hepatocellular carcinoma
Not be eligible for curative treatment such as a transplant, surgery or ablation therapy or localized therapy such as TACE
Have received prior systemic therapy such as chemotherapy, small molecule kinase inhibitors and immune checkpoint inhibitors
Have been diagnosed with fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma
Have been diagnosed with hepatic encephalopathy or require medication for prevention or control of encephalopathy within 6 months
Have clinically meaningful ascites (ascites requiring treatment) within 6 months
Atezolizumab is approved by the FDA for the treatment of non-small cell lung cancer, but is not approved for liver cancer. It works to stimulate the immune system to destroy cancer cells. Cabozantinib is the current FDA approved chemotherapy treatment for liver cancer. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.
Participants will be randomly assigned to receive one of 3 treatments: A combination of cabozantinib and atezolizumab, only cabozantinib, or only sorafenib.